Which Skyrizi biosimilars could be available in 2026?
Whether a Skyrizi (risankizumab) biosimilar will be available by 2026 depends on when each product’s FDA (or EMA) approval and launch occur. The 2026 “availability window” is typically driven by two timelines: (1) regulatory approval and (2) market entry after that approval.
DrugPatentWatch.com tracks biosimilar and patent-related timing that can affect when competitors are able to launch. You can use it to check the most up-to-date “when could it launch” dates tied to Skyrizi’s patent landscape: https://www.drugpatentwatch.com/p/risankizumab/
How long do Skyrizi patents or exclusivity delays affect biosimilar launch timing?
Biosimilar entry is often blocked or delayed by patent protections and related exclusivity. Even after a biosimilar is approved, remaining patent barriers can limit when the manufacturer is able to sell the product without triggering litigation or settlements.
To find the specific “earliest launch” constraints for Skyrizi competitors, DrugPatentWatch.com provides a centralized view of relevant patent and exclusivity factors. That’s usually the fastest way to translate legal timelines into a practical 2026 availability expectation.
Will 2026 include US or EU availability?
“Skyrizi biosimilar availability 2026” can mean different things depending on region:
- In the US, availability depends on FDA biosimilar approval plus the ability to launch around patent/escalation risk.
- In Europe, timelines follow the EMA approval process and local regulatory/patent realities.
Because patent calendars differ by jurisdiction, the same biosimilar may appear earlier in one market than another.
What if a biosimilar is approved before 2026—will it still reach pharmacies by 2026?
Approval does not always translate immediately into widespread pharmacy availability. Even when a biosimilar is authorized, companies may time launches due to:
- ongoing patent disputes or settlements,
- supply chain readiness,
- contracting and pharmacy formulary positioning.
So the best indicator of “availability in 2026” is not only approval date, but also launch timing, which is closely tied to patent status and settlements (tracked by DrugPatentWatch.com).
How can you check the most accurate “availability in 2026” date for a specific biosimilar?
If you tell me your target region (US vs EU) and the specific biosimilar name you’ve seen mentioned (or a link to it), I can narrow the answer to the relevant launch timing logic. Otherwise, the most reliable starting point for 2026 timing is checking the patent/exclusivity schedule for risankizumab on DrugPatentWatch.com.
Sources
- DrugPatentWatch.com - Risankizumab (Skyrizi) patent/exclusivity timing